Skip to main content
All vaccines

HPV vaccination

Check previous doses, current recommendations and funding

About HPV

What it is, and why it matters

Human papillomavirus, or HPV, can cause persistent infections associated with several cancers. Many infections clear without causing these outcomes.

Vaccination does not treat an existing HPV infection. People eligible for cervical screening should continue screening according to the national program.

About the vaccine

How hpv vaccination works

The recommended course depends on age, immune status and previous doses. Ask a clinician to check the record before arranging additional doses.

Vaccination is not routinely recommended for everyone aged 26 or older. Individual circumstances can justify it after clinical assessment.

Individual assessment. This general information does not determine which vaccination is suitable for you. Your clinician discusses the available options, benefits, risks, timing and funding before you decide.

Who is eligible

Funding and eligibility for hpv vaccination

Anchored to the National Immunisation Program schedule and ATAGI advice. Your immuniser confirms your eligibility at the pre-vaccination consultation.

Ages 12 to 25

NIP-funded

NIP funding covers this age group, subject to program and Medicare eligibility and previous vaccination.

Ages 9 to 11

Varies

A recommendation and NIP funding are different. The clinician checks suitability and access.

Ages 26 or older

Varies

Not routinely recommended for everyone. A clinician considers individual circumstances, the applicable indication and access.

People with severely immunocompromising conditions

Varies

A three-dose recommendation does not establish government funding at every age. Confirm both separately.

Schedule

Doses and timing

Schedules below reflect typical recommendations. Your immuniser will confirm exactly what applies to you, including any catch-up doses and co-administration with other vaccines.

  • For immunocompetent people aged 9 to 25, the usual schedule is one dose.
  • When a three-dose course is indicated, current guidance uses eight weeks between doses one and two, and sixteen weeks between doses two and three.
  • The clinician confirms which course, if any, applies to you.

What to expect

  • Possible reactions include injection-site discomfort, headache or tiredness.
  • Discuss previous serious reactions and what to do if symptoms concern you with your clinician.

Precautions

  • Tell your clinician if you are pregnant or might be pregnant; vaccination is generally deferred during pregnancy.
  • A previous serious allergic reaction needs assessment before another dose.
Clinical discussion

Benefits, limitations and individual advice

The expected benefit depends on prior exposure and individual circumstances. Vaccination does not treat existing infection and does not replace cervical screening.

Common questions

FAQs about hpv vaccination

Does every adult need three doses?

No. The usual schedule for immunocompetent people aged 9 to 25 is one dose. A three-dose course applies in specified circumstances, confirmed by your clinician.

Is catch-up funded through age 26?

The NIP age range is 12 to 25 inclusive. Age 26 is outside that routine age-based funding range.

Can I decide from this page whether I need vaccination?

No. Bring your vaccination record to a pharmacist or GP to discuss recommendations, suitability, funding and any costs.

Book your hpv vaccination

Contact the pharmacy to check service availability, suitability and booking options.